Corcept Therapeutics
CORT
Corcept Therapeutics (CORT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.36
- EPS estimate
- $0.02
- EPS surprise
- +1381.48%
- Revenue surprise
- +15.83%
- Revenue
- $256.1M
- Revenue estimate
- $221.1M
- Reported
- Jul 29, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $0.02 | $0.36 | +1381.48% | $256.1M | SEC |
| Q1 2026 | Apr 30, 2026 | −$0.11 | −$0.30 | −176.50% | $164.9M | SEC |
| Q4 2025 | Feb 24, 2026 | $0.33 | $0.20 | −39.30% | $202.1M | SEC |
| Q3 2025 | Nov 4, 2025 | $0.16 | $0.16 | −2.26% | $207.6M | SEC |
| Q2 2025 | Jul 31, 2025 | $0.19 | $0.29 | +54.67% | $194.4M | SEC |
| Q1 2025 | May 5, 2025 | $0.14 | $0.17 | +19.30% | $157.2M | SEC |
| Q4 2024 | Feb 26, 2025 | $0.43 | $0.26 | −39.01% | $181.9M | SEC |
| Q3 2024 | Oct 30, 2024 | $0.28 | $0.41 | +45.44% | $182.5M | SEC |
| Q2 2024 | Jul 29, 2024 | $0.23 | $0.32 | +39.13% | $163.8M | SEC |
| Q1 2024 | May 1, 2024 | $0.22 | $0.25 | +13.64% | $146.8M | SEC |
| Q4 2023 | Feb 15, 2024 | $0.26 | $0.28 | +8.49% | $135.4M | SEC |
| Q3 2023 | Nov 1, 2023 | $0.22 | $0.28 | +28.26% | $123.6M | SEC |
| Q2 2023 | Aug 2, 2023 | $0.15 | $0.25 | +66.67% | $117.7M | SEC |
| Q1 2023 | May 3, 2023 | $0.20 | $0.14 | −29.51% | $105.7M | SEC |
| Q4 2022 | Feb 28, 2023 | $0.24 | $0.14 | −41.59% | $103.1M | SEC |
| Q3 2022 | Nov 3, 2022 | $0.23 | $0.30 | +28.21% | $101.7M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.24 | $0.24 | +1.39% | $103.4M | SEC |
| Q1 2022 | May 5, 2022 | $0.23 | $0.20 | −13.68% | $93.7M | SEC |
| Q4 2021 | Feb 15, 2022 | $0.23 | $0.26 | +15.56% | $98.8M | SEC |
| Q3 2021 | Nov 3, 2021 | $0.22 | $0.24 | +11.63% | $96.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Corcept Therapeutics (CORT) last report earnings?
Corcept Therapeutics last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did CORT beat earnings estimates?
Yes. Corcept Therapeutics reported EPS of $0.36 for Q2 2026 against a $0.02 estimate — a 1381.48% beat.
How much revenue did CORT report last quarter?
Corcept Therapeutics reported $256.1M in revenue for Q2 2026, against a consensus estimate of $221.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.